Journal: Zhonghua yi xue za zhi
The Breast Cancer Committee of the Chinese Society of Clinical Oncology has updated the 2025 expert consensus on the diagnosis and treatment of HER2-targeted breast cancer. This update integrates the latest clinical evidence and domestic experience.
Key points include:
- Precise HER2 testing: Emphasizing attention to spatiotemporal heterogeneity and clear definitions for low and ultra-low expression.
- Neoadjuvant therapy: Dual HER2 blockade with trastuzumab and pertuzumab is preferred, tailored to patient characteristics.
- Adjuvant therapy: Decisions depend on pathological response and patient risk.
- Relapsed and metastatic treatment: Strategies should consider trastuzumab sensitivity and resistance, with individualized approaches for special populations.
- Low/ultra-low HER2 expression: Patients may benefit from novel antibody-drug conjugates.
Overall, individualized treatment guided by standardized testing and consensus recommendations aims to improve patient outcomes.